Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Jan 18;292(6514):155–157. doi: 10.1136/bmj.292.6514.155

Human insulin.

J Pickup
PMCID: PMC1339031  PMID: 3080111

Full text

PDF
155

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BROWN H., SANGER F., KITAI R. The structure of pig and sheep insulins. Biochem J. 1955 Aug;60(4):556–565. doi: 10.1042/bj0600556. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bolli G., de Feo P., Compagnucci P., Cartechini M. G., Angeletti G., Santeusanio F., Brunetti P., Gerich J. E. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes. 1983 Feb;32(2):134–141. doi: 10.2337/diab.32.2.134. [DOI] [PubMed] [Google Scholar]
  3. Bottermann P., Gyaram H., Wahl K., Ermler R., Lebender A. Insulin concentrations and time-action profiles of three different intermediate-acting insulin preparations in nondiabetic volunteers under glucose-controlled glucose infusion technique. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):43–52. doi: 10.2337/diacare.5.2.s43. [DOI] [PubMed] [Google Scholar]
  4. Brunfeldt K., Deckert T., Thomsen J. Human crystalline insulin from non-diabetic and diabetic patients. Acta Endocrinol (Copenh) 1969 Mar;60(3):543–549. doi: 10.1530/acta.0.0600543. [DOI] [PubMed] [Google Scholar]
  5. Chawdhury S. A., Dodson E. J., Dodson G. G., Reynolds C. D., Tolley S. P., Blundell T. L., Cleasby A., Pitts J. E., Tickle I. J., Wood S. P. The crystal structures of three non-pancreatic human insulins. Diabetologia. 1983 Dec;25(6):460–464. doi: 10.1007/BF00284451. [DOI] [PubMed] [Google Scholar]
  6. Clark A. J., Adeniyi-Jones R. O., Knight G., Leiper J. M., Wiles P. G., Jones R. H., Keen H., MacCuish A. C., Ward J. D., Watkins P. J. Biosynthetic human insulin in the treatment of diabetes. A double-blind crossover trial in established diabetic patients. Lancet. 1982 Aug 14;2(8294):354–357. doi: 10.1016/s0140-6736(82)90548-7. [DOI] [PubMed] [Google Scholar]
  7. Fineberg S. E., Galloway J. A., Fineberg N. S., Rathbun M. J., Hufferd S. Immunogenicity of recombinant DNA human insulin. Diabetologia. 1983 Dec;25(6):465–469. doi: 10.1007/BF00284452. [DOI] [PubMed] [Google Scholar]
  8. Francis A. J., Hanning I., Alberti K. G. The influence of insulin antibody levels on the plasma profiles and action of subcutaneously injected human and bovine short acting insulins. Diabetologia. 1985 Jun;28(6):330–334. doi: 10.1007/BF00283138. [DOI] [PubMed] [Google Scholar]
  9. Francis A. J., Home P. D., Hanning I., Alberti K. G., Tunbridge W. M. Intermediate acting insulin given at bedtime: effect on blood glucose concentrations before and after breakfast. Br Med J (Clin Res Ed) 1983 Apr 9;286(6372):1173–1176. doi: 10.1136/bmj.286.6372.1173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Galloway J. A., Peck F. B., Jr, Fineberg S. E., Spradlin C. T., Marsden J. H., Allemenos D., Ingulli-Fattic J. The U.S. "new patient" and "transfer" studies. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):135–139. doi: 10.2337/diacare.5.2.s135. [DOI] [PubMed] [Google Scholar]
  11. Goeddel D. V., Kleid D. G., Bolivar F., Heyneker H. L., Yansura D. G., Crea R., Hirose T., Kraszewski A., Itakura K., Riggs A. D. Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci U S A. 1979 Jan;76(1):106–110. doi: 10.1073/pnas.76.1.106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gray R. S., Cowan P., di Mario U., Elton R. A., Clarke B. F., Duncan L. J. Influence of insulin antibodies on pharmacokinetics and bioavailability of recombinant human and highly purified beef insulins in insulin dependent diabetics. Br Med J (Clin Res Ed) 1985 Jun 8;290(6483):1687–1691. doi: 10.1136/bmj.290.6483.1687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Guy R. J., Richards F., Edmonds M. E., Watkins P. J. Diabetic autonomic neuropathy and iritis: an association suggesting an immunological cause. Br Med J (Clin Res Ed) 1984 Aug 11;289(6441):343–345. doi: 10.1136/bmj.289.6441.343. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Heding L. G., Marshall M. O., Persson B., Dahlquist G., Thalme B., Lindgren F., Akerblom H. K., Rilva A., Knip M., Ludvigsson J. Immunogenicity of monocomponent human and porcine insulin in newly diagnosed type 1 (insulin-dependent) diabetic children. Diabetologia. 1984 Jul;27 (Suppl):96–98. doi: 10.1007/BF00275658. [DOI] [PubMed] [Google Scholar]
  15. Holman R. R., Steemson J., Darling P., Reeves W. G., Turner R. C. Human ultralente insulin. Br Med J (Clin Res Ed) 1984 Mar 3;288(6418):665–668. doi: 10.1136/bmj.288.6418.665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Home P. D., Mann N. P., Hutchison A. S., Park R., Walford S., Murphy M., Reeves W. G. A fifteen-month double-blind cross-over study of the efficacy and antigenicity of human and pork insulins. Diabet Med. 1984 Jul;1(2):93–98. doi: 10.1111/j.1464-5491.1984.tb01936.x. [DOI] [PubMed] [Google Scholar]
  17. Keen H., Glynne A., Pickup J. C., Viberti G. C., Bilous R. W., Jarrett R. J., Marsden R. Human insulin produced by recombinant DNA technology: safety and hypoglycaemic potency in healthy men. Lancet. 1980 Aug 23;2(8191):398–401. doi: 10.1016/s0140-6736(80)90443-2. [DOI] [PubMed] [Google Scholar]
  18. Kemmer F. W., Sonnenberg G., Cüppers H. J., Berger M. Absorption kinetics of semisynthetic human insulin and biosynthetic (recombinant DNA) human insulin. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):23–28. doi: 10.2337/diacare.5.2.s23. [DOI] [PubMed] [Google Scholar]
  19. Kurtz A. B., Nabarro J. D. Circulating insulin-binding antibodies. Diabetologia. 1980 Oct;19(4):329–334. doi: 10.1007/BF00280515. [DOI] [PubMed] [Google Scholar]
  20. Ludvigsson J. Insulin antibodies in diabetic children treated with monocomponent porcine insulin from the onset: relationship to B-cell function and partial remission. Diabetologia. 1984 Feb;26(2):138–141. doi: 10.1007/BF00281121. [DOI] [PubMed] [Google Scholar]
  21. Madsbad S., Alberti K. G., Binder C., Burrin J. M., Faber O. K., Krarup T., Regeur L. Role of residual insulin secretion in protecting against ketoacidosis in insulin-dependent diabetes. Br Med J. 1979 Nov 17;2(6200):1257–1259. doi: 10.1136/bmj.2.6200.1257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Madsbad S., Hilsted J., Krarup T., Sestoft L., Christensen N. J., Tronier B. The importance of plasma free insulin and counterregulatory hormones for the recovery of blood glucose following hypoglycaemia in type 1 diabetics. Acta Endocrinol (Copenh) 1985 Feb;108(2):224–230. doi: 10.1530/acta.0.1080224. [DOI] [PubMed] [Google Scholar]
  23. Maneschi F., Fineberg S. E., Kohner E. M. Successful treatment of immune-mediated insulin resistance by human insulin (recombinant DNA). Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):175–179. doi: 10.2337/diacare.5.2.s175. [DOI] [PubMed] [Google Scholar]
  24. Mann N. P., Johnston D. I., Reeves W. G., Murphy M. A. Human insulin and porcine insulin in the treatment of diabetic children: comparison of metabolic control and insulin antibody production. Br Med J (Clin Res Ed) 1983 Nov 26;287(6405):1580–1582. doi: 10.1136/bmj.287.6405.1580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Markussen J., Damgaard U., Pingel M., Snel L., Sørensen A. R., Sørensen E. Human insulin (Novo): chemistry and characteristics. Diabetes Care. 1983 Mar-Apr;6 (Suppl 1):4–8. [PubMed] [Google Scholar]
  26. Miller W. L., Baxter J. D. Recombinant DNA--a new source of insulin. Diabetologia. 1980 Jun;18(6):431–436. doi: 10.1007/BF00261696. [DOI] [PubMed] [Google Scholar]
  27. Mylvaganam R., Stowers J. M., Steel J. M., Wallace J., MacHendry J. C., Wright A. D. Insulin immunogenicity in pregnancy: maternal and fetal studies. Diabetologia. 1983 Jan;24(1):19–25. doi: 10.1007/BF00275942. [DOI] [PubMed] [Google Scholar]
  28. NICOL D. S., SMITH L. F. Amino-acid sequence of human insulin. Nature. 1960 Aug 6;187:483–485. doi: 10.1038/187483a0. [DOI] [PubMed] [Google Scholar]
  29. Owens D. R., Jones I. R., Birtwell A. J., Burge C. T., Luzio S., Davies C. J., Heyburn P., Heding L. G. Study of porcine and human isophane (NPH) insulins in normal subjects. Diabetologia. 1984 Apr;26(4):261–265. doi: 10.1007/BF00283647. [DOI] [PubMed] [Google Scholar]
  30. Peacock I., Tattersall R. B., Taylor A., Douglas C. A., Reeves W. G. Effects of new insulins on insulin and C-peptide antibodies, insulin dose, and diabetic control. Lancet. 1983 Jan 22;1(8317):149–152. doi: 10.1016/s0140-6736(83)92756-3. [DOI] [PubMed] [Google Scholar]
  31. Pickup J. C., Bilous R. W., Viberti G. C., Keen H., Jarrett R. J., Glynne A., Cauldwell J., Root M., Rubenstein A. H. Plasma insulin and C-peptide after subcutaneous and intravenous administration of human insulin (recombinant DNA) and purified porcine insulin in healthy men. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):29–34. doi: 10.2337/diacare.5.2.s29. [DOI] [PubMed] [Google Scholar]
  32. Pickup J. C., Keen H., Viberti G. C., White M. C., Kohner E. M., Parsons J. A., Alberti K. G. Continuous subcutaneous insulin infusion in the treatment of diabetes mellitus. Diabetes Care. 1980 Mar-Apr;3(2):290–300. doi: 10.2337/diacare.3.2.290. [DOI] [PubMed] [Google Scholar]
  33. Pullen R. A., Lindsay D. G., Wood S. P., Tickle I. J., Blundell T. L., Wollmer A., Krail G., Brandenburg D., Zahn H., Gliemann J. Receptor-binding region of insulin. Nature. 1976 Feb 5;259(5542):369–373. doi: 10.1038/259369a0. [DOI] [PubMed] [Google Scholar]
  34. Reeves W. G., Allen B. R., Tattersall R. B. Insulin-induced lipoatrophy: evidence for an immune pathogenesis. Br Med J. 1980 Jun 21;280(6230):1500–1503. doi: 10.1136/bmj.280.6230.1500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Rosak C., Althoff P. H., Enzmann F., Schöffling K. Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):82–89. doi: 10.2337/diacare.5.2.s82. [DOI] [PubMed] [Google Scholar]
  36. SMITH L. F. ISOLATION OF INSULIN FROM PANCREATIC EXTRACTS USING CARBOXYMETHYL AND DIETHYLAMINOETHYL CELLULOSES. Biochim Biophys Acta. 1964 Feb 10;82:231–236. doi: 10.1016/0304-4165(64)90293-4. [DOI] [PubMed] [Google Scholar]
  37. Schlüter K. J., Petersen K. G., Sontheimer J., Enzmann F., Kerp L. Different counterregulatory responses to human insulin (recombinant DNA) and purified pork insulin. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):78–81. doi: 10.2337/diacare.5.2.s78. [DOI] [PubMed] [Google Scholar]
  38. Skyler J. S. Human insulin of recombinant DNA origin: clinical potential. Diabetes Care. 1982 Nov-Dec;5 (Suppl 2):181–186. doi: 10.2337/diacare.5.2.s181. [DOI] [PubMed] [Google Scholar]
  39. Smith L. F. Amino acid sequences of insulins. Diabetes. 1972;21(2 Suppl):457–460. doi: 10.2337/diab.21.2.s457. [DOI] [PubMed] [Google Scholar]
  40. Vaughan N. J., Matthews J. A., Kurtz A. B., Nabarro J. D. The bioavailability of circulating antibody-bound insulin following insulin withdrawal in Type 1 (insulin-dependent) diabetes. Diabetologia. 1983 May;24(5):355–358. doi: 10.1007/BF00251824. [DOI] [PubMed] [Google Scholar]
  41. Yue D. K., Baxter R. C., Turtle J. R. C-peptide secretion and insulin antibodies as determinants of stability in diabetes mellitus. Metabolism. 1978 Jan;27(1):35–44. doi: 10.1016/0026-0495(78)90121-x. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES